SYBX stock icon

Synlogic
SYBX

$1.65
5.73%

Market Cap: 19.3M

 

About: Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.

Employees: 6

0
Funds holding %
of 6,702 funds
Analysts bullish %
News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

100% more funds holding in top 10

Funds holding in top 10: 1 [Q4 2023] → 2 (+1) [Q1 2024]

8.12% more ownership

Funds ownership: 51.32% [Q4 2023] → 59.44% (+8.12%) [Q1 2024]

0% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 4

29% less funds holding

Funds holding: 24 [Q4 2023] → 17 (-7) [Q1 2024]

32% less capital invested

Capital invested by funds: $18.2M [Q4 2023] → $12.4M (-$5.76M) [Q1 2024]

78% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 9

Research analyst outlook

1 Wall Street Analyst provided 1 year price forecasts over the past 6 months

Low target
$1
39%
downside
Avg. target
$1
39%
downside
High target
$1
39%
downside

1 analyst rating

positive
0%
neutral
100%
negative
0%
Leerink Partners
Joseph Schwartz
39%downside
$1
Market Perform
Downgraded
9 Feb 2024

Financial journalist opinion